secwatch.observer — SEC 8-K summary
======================================

Issuer:     HUMANIGEN, INC (—)
CIK:        0001293310
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001214659-23-003011
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humanigen receives Nasdaq delisting notice; settles Avid dispute for $3M
------------------------------------------------------------------------

- Nasdaq notified Humanigen it failed to regain minimum bid price compliance by Feb 20, 2023; not eligible for second extension.
- Company also fails stockholders' equity initial listing requirement and market value below $35M for continued listing.
- Company intends to request a hearing before Nasdaq Hearings Panel by Feb 28, 2023; stay of suspension pending hearing.
- Settled Lenzilumab disputes with Avid Bioservices for $3.0M one-time payment; conditional dismissal after 120 days if no bankruptcy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293310/000121465923003011/0001214659-23-003011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293310/000121465923003011/g2232308k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-23-003011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer